{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:13:02Z","timestamp":1790154782800,"version":"4.0.1"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Over the past 10 years, treatment of non\u2013small cell lung cancer (NSCLC) has been continually revolutionized. However, standard clinical trials may not reflect current multiple lines of treatment and corresponding outcomes in a timely manner.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate outcomes associated with new treatment of NSCLC in a clinical setting.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included patients with NSCLC between January 1, 2010, and November 30, 2020, who received any anticancer treatment at Samsung Medical Center in Korea. Data were analyzed from November 2021 through February 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Clinical and pathological stage, histology, and major druggable sequence variation, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1<\/jats:italic>, RET<\/jats:italic>, MET<\/jats:italic> exon 14 skipping, BRAF<\/jats:italic> V600E, KRAS<\/jats:italic> G12C, and NTRK<\/jats:italic> between 2 periods (period I: 2010-2015 vs period II: 2016\u20132020).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the 3-year survival rate of NSCLC. Secondary outcomes included median overall survival, progression-free survival, and recurrence-free survival.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 21\u202f978 patients with NSCLC (median [range] age at diagnosis, 64.1 [57.0-71.0] years; 13\u202f624 males [62.0%]), there were 10\u202f110 patients in period I and 11\u202f868 patients in period II; adenocarcinoma (AD) was the predominant histology (7112 patients [70.3%] in period I and 8813 patients [74.3%] in period II). There were 4224 never smokers [41.8%] in period I and 5292 never smokers [44.6%] in period II. Compared with patients in period I, patients during period II were more likely to undergo molecular tests in the AD (5678 patients [79.8%] vs 8631 patients [97.9%]) and non-AD (1612 of 2998 patients [53.8%] and 2719 of 3055 patients [89.0%]) groups. In patients with AD in period I, 3-year survival rates were 92.8% (95% CI, 91.8%-93.7%), 72.4% (95% CI, 68.3%-76.8%), 56.7% (95% CI, 53.4%-60.2%), and 28.7% (95% CI, 27.0%-30.4%) for stage I, II, III, and IV, respectively. In period II, 3-year survival rates of patients with AD were 95.1% (95% CI, 94.4%-95.9%), 82.5% (95% CI, 79.1%-86.1%), 65.1% (95% CI, 61.8%-68.6%), and 42.4% (95% CI, 40.3%-44.7%) for each stage, respectively. In patients without AD, 3-year survival rates were 72.0% (95% CI, 68.8%-75.3%), 60.0% (95% CI, 56.2%-64.1%), 38.9% (95% CI, 35.6%-42.5%), and 9.7% (95% CI, 7.9%-12.1%) for each stage in period I. In period II, the 3-year survival rates of patients without AD were 79.3% (95% CI, 76.3%-82.4%), 67.3% (95% CI, 62.8%-72.1%), 48.2% (95% CI, 44.5%-52.3%), and 18.1% (95% CI, 15.1%-21.6%) for each stage.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of 10 years of clinical data, survival outcomes were improved across all stages, with larger increases in patients with stage III to IV disease. The incidence of never-smokers and the use of molecular testing increased.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.2002","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:01:21Z","timestamp":1678978881000},"page":"e232002","source":"Crossref","is-referenced-by-count":38,"title":["Trends in Survival Rates of Non\u2013Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020"],"prefix":"10.1001","volume":"6","author":[{"given":"Sang Ah","family":"Chi","sequence":"first","affiliation":[{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeon","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehhoon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunga","family":"Kim","sequence":"additional","affiliation":[{"name":"Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea"},{"name":"Department of Data Convergence and Future Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"6","key":"zoi230092r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi230092r2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2020.203","article-title":"Prediction of cancer incidence and mortality in Korea, 2020.","volume":"52","author":"Jung","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"21","key":"zoi230092r3","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi230092r4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi230092r5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi230092r6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer.","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi230092r7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/2159-8290.CD-NB2019-128","article-title":"MCLA-128 fights NRG1 fusion-positive cancers.","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"zoi230092r8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer.","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi230092r9","doi-asserted-by":"publisher","first-page":"OF5","DOI":"10.1158\/2159-8290.CD-NB2021-0314","article-title":"TROP2 ADC intrigues in NSCLC.","volume":"11","author":"TROP2 ADC Intrigues in NSCLC","year":"2021","journal-title":"Cancer Discov"},{"issue":"10","key":"zoi230092r10","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.21037\/tlcr","article-title":"Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system.","volume":"10","author":"Jung","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"zoi230092r11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin J Cancer"},{"issue":"7","key":"zoi230092r12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/JTO.0b013e3181e2f607","article-title":"Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California regional cancer registry databases.","volume":"5","author":"Kawaguchi","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"1","key":"zoi230092r13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1440-1843.2003.00433.x","article-title":"The impact of tobacco on lung health in China.","volume":"8","author":"Zhang","year":"2003","journal-title":"Respirology"},{"issue":"18","key":"zoi230092r14","doi-asserted-by":"publisher","first-page":"9901","DOI":"10.3390\/ijerph18189901","article-title":"Effectiveness of national residential smoking cessation program.","volume":"18","author":"Park","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"zoi230092r15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4143\/crt.2018.464","article-title":"Development of protocol for Korean Lung Cancer Screening Project (K-LUCAS) to evaluate effectiveness and feasibility to implement national cancer screening program.","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res Treat"},{"key":"zoi230092r16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis.","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"issue":"19","key":"zoi230092r17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230092r18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi230092r19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi230092r20","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2802526\/chi_2023_oi_230092_1678296510.99453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:01:24Z","timestamp":1678978884000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2802526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.2002","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}